COVA4231

COVA4231 is a preclinical CD3/CD33 bispecific FynomAb engineered on a full-length IgG scaffold to redirect T cells against CD33-positive acute myeloid leukemia (AML) cells.[1][2][6] Developed using Covagen’s FynomAb platform, it consists of an intact anti-CD3 antibody genetically fused to a CD33-binding Fynomer, a small engineered protein domain that functions analogously to an antibody fragment but with high stability and affinity.[2] By simultaneously binding CD3 on CD4+ and CD8+ T cells and CD33 on AML blasts, COVA4231 induces T-cell activation, cytokine secretion (including IFN-γ and IL-2), and potent T cell–mediated cytotoxicity against CD33-expressing leukemia cell lines and primary AML samples in vitro, and it reduces tumor burden in humanized AML mouse models with intermittent dosing enabled by its IgG-like half-life of approximately two weeks in vivo.[1][2] The molecule is being developed by Covagen (acquired by Janssen/Johnson & Johnson) as a next-generation, extended–half-life T cell–engaging bispecific antibody candidate for the treatment of CD33-positive AML.[1][2][6]

Other names

CD3/CD33 bispecific FynomAb